Quest Diagnostics Stock - Q2 2026 earnings date confirmed
Published on 06/17/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:47 CET. Details in the imprint.
Quest Diagnostics (US74834L1008) has scheduled the release of its second-quarter 2026 financial results for Thursday, July 23, 2026, before the market opens, according to a PR Newswire announcement on June 17, 2026. The company will host a conference call that morning at 8:30 a.m. Eastern Time to discuss the figures.
All news and data on Quest Diagnostics stock
Key announcements like the newly confirmed Q2 2026 earnings date shape expectations for Quest Diagnostics and help investors position ahead of results and guidance.
Details of the Q2 2026 announcement
In its June 17 statement, Quest Diagnostics said it will publish second-quarter 2026 results ahead of the U.S. market open on July 23, 2026, with a same-day earnings call at 8:30 a.m. Eastern. The PR Newswire release carried by Morningstar also lists dial-in details for U.S. and international participants.
The company plans to post the earnings release and a live webcast on its investor relations site, with a telephone and online replay available from the morning of July 23 until midnight Eastern Time on August 6, 2026. The call replay will not require a passcode, according to the notice.
Wednesday focus on operations and strategy
Quest Diagnostics positions itself as a leading provider of diagnostic information services in the United States, focusing on routine testing, advanced clinical diagnostics and health IT solutions for physicians, hospitals and payers. The company frequently highlights its nationwide laboratory and patient service center network as a structural advantage.
Management has in recent years emphasized operational efficiency and digital initiatives, including analytics and automation programs aimed at improving turnaround times and cost structures in its laboratories. Job postings for leadership roles in digital quality, analytics and business transformation underscore this ongoing focus on Lean methods and data-driven process improvement.
How Quest Diagnostics makes its money
Quest Diagnostics primarily generates revenue by performing diagnostic tests on blood and other specimens ordered by healthcare providers, employers and insurers, and by delivering the resulting information back to clinicians and patients. The company also offers specialized testing in areas such as oncology, cardiometabolic disorders and infectious diseases, as well as health IT connectivity services.
Where the stock trades today
The shares of Quest Diagnostics (US74834L1008) trade on the New York Stock Exchange under the ticker DGX, with the latest available quote in U.S. dollars on NYSE during regular U.S. trading hours.
Key facts on Quest Diagnostics stock
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- WKN: 922852
- Ticker: DGX
- Venue: NYSE
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: S&P 500
- Next earnings date: 07/23/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
